NewKerala.com

West Asia Crisis Drives Up Pharma Costs, Supply Chains Under Pressure

The ongoing West Asia crisis is increasing cost pressures on India's pharmaceutical sector through higher freight, insurance, and critical solvent prices. Industry leaders emphasize that ensuring the uninterrupted supply of medicines to over 200 countries remains the top priority. Multiple government departments are coordinating with the industry to maintain the availability of inputs and keep supply chains functional. The sector, a strategic pillar of the economy, has set an ambitious target of contributing USD 450 billion by 2047 through innovation.

Key Points: West Asia Crisis Raises Pharma Freight, Insurance & Input Costs

  • Rising freight & insurance costs
  • Solvent price increases
  • Govt-industry coordination on supply
  • Uninterrupted medicine supply focus
2 min read

Freight, insurance, input costs rise amid West Asia crisis, pharma supply chain under pressure: IPA

Indian pharma faces rising freight, insurance & solvent costs due to West Asia crisis. Industry & govt focus on ensuring global medicine supply.

"Yes, there has been a definite increase in the freight cost... the primary task... is to ensure that the products are available - Sudarshan Jain"

New Delhi, April 14

India's pharmaceutical sector is witnessing rising cost pressures due to the ongoing West Asia crisis, with increased freight, insurance, and input costs impacting the supply chain, said Sudarshan Jain, General Secretary, Indian Pharmaceutical Alliance.

In an exclusive conversation with ANI on Tuesday, talking about the impact of the crisis, Jain said there has been a definite increase in freight costs, along with a rise in insurance expenses and solvent prices, which are critical inputs for pharmaceutical manufacturing.

"Yes, there has been a definite increase in the freight cost. There is an insurance cost which has gone up and there is a cost increase in the solvent. We are working very closely with the government and the primary task at the moment is to ensure that the products are available because we owe a lot to the world that we supply to more than 200 countries and the patients around the world depend on us," he said.

Despite these challenges, Jain emphasised that the primary focus of the industry and government is to ensure the uninterrupted availability of medicines, both domestically and globally.

He added that multiple government departments, including the Department of Pharmaceuticals and the Ministry of Commerce, are working in coordination with the industry to ensure that critical inputs remain available and supply chains function smoothly.

"The Department of Pharmaceuticals, Commerce Ministry, and the industry are working together to ensure that inputs are available and products are supplied on time to patients globally," Jain noted.

Highlighting the importance of the sector, Jain also said the pharmaceutical industry is a strategic pillar of the Indian economy, contributing USD 30 billion in exports and USD 30 billion to the domestic market.

India supplies medicines to more than 200 countries and has the highest number of USFDA-approved manufacturing plants, reinforcing its position as a key global supplier of pharmaceuticals.

Looking ahead, Jain said the industry has set an ambitious target of contributing USD 450 billion by 2047, with innovation playing a central role.

"The sector can be a very great contributor to the country. What will play an important role going forward is innovation, especially affordable innovation at scale," he said.

Jain further said that industry leaders have aligned on a vision to develop more than 100 products by 2047, with a focus on strengthening regulatory frameworks and making India a global benchmark in pharmaceuticals.

- ANI

Share this article:

Reader Comments

S
Sarah B
It's reassuring to see the industry and government working together. The priority on ensuring supply chain continuity is crucial, especially when so many countries depend on Indian medicines. Hope they find a solution soon.
P
Priya S
The USD 450 billion target by 2047 is very ambitious! But with the current geopolitical issues causing cost pressures, the focus on "affordable innovation" is the right path. Jai Hind!
A
Arjun K
This shows how global conflicts hit our local industries. We are the pharmacy of the world, but our supply chains are vulnerable. Time to reduce dependency on certain routes and materials? 🤔
K
Karthik V
While the collaboration is good, I hope there is transparency. A slight respectful criticism: we often hear about targets and coordination, but the public rarely sees a clear roadmap on how such cost crises are actually mitigated for end consumers.
M
Michael C
The statistic about supplying to over 200 countries is impressive. It underscores India's critical role in global health. Any disruption here would have worldwide consequences. The industry deserves support.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50